Japan-based Eisai Co. and Kyorin Pharmaceutical Co. have announced that Eisai (Thailand) Marketing Co., a subsidiary of Eisai, has launched overactive bladder treatment Beova Tablets (generic name vibegron) in Thailand.
In 2021, Eisai acquired exclusive development and marketing rights from Kyorin for the agent in ASEAN member states Thailand, the Philippines, Malaysia, and Brunei. Eisai Thailand submitted an application for marketing authorisation in Thailand in March 2023, and received approval in June 2024.
This launch is the first within Eisai’s licensed region. In addition to the release in Thailand, approval has also been obtained in the Philippines and Malaysia, with preparations underway for market entry.
Overactive bladder (OAB) is a urological condition with trouble in pooling urine in the bladder. It's predominant symptom is an urge to urinate, which is often accompanied by frequent urination and nocturia, and in some cases by urge urinary incontinence. One of the major problems of OAB is the fact that patients refrain from leaving the house due to anxiety about going to the bathroom, cannot get enough sleep at night, or face limitations in their daily activities, which could lead to significantly-reduced quality of life.
Appropriate treatment is necessary for OAB, which increases with age but has also been reported to becaused by brain or spinal cord disorders such as cerebrovascular diseases (cerebral hemorrhage and cerebral infarction), Parkinson's disease, and benign prostatic hyperplasia. The prevalence of OAB in Thailand is reported to be 15.8%.
This agent is a selective B3-adrenergic receptor agonist administered once daily, acting selectively on B3 receptors in the bladder, relaxing the bladder to enhance urine collection, and consequently improving the symptoms of urgency, urinary frequency and urge urinary incontinence associated with OAB.
